Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 7/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | MGMT | P16455 | 5/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopurine SCHEMBL5634 | 0.89 | ALDH1A1 (1.00) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL28208518 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL28075430 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL357699 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL29056388 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL3144589 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL31379734 | 0.87 | ALDH1A1 (0.96) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL6056061 | 0.85 | ALDH1A1 (0.92) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL1528159 | 0.81 | ALDH1A1 (0.82) | ALDH1A1RXFP1KDM4EPAK1PDPK1 | |
| 2-Aminopurine SCHEMBL4342854 | 0.79 | ALDH1A1 (0.79) | ALDH1A1RXFP1KDM4EPAK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20080280850-A1 | Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus | IDENIX PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1912643-A2 | 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING INFECTIONS WITH FLAVIVIRIDAE | Idenix (Cayman) Limited (KY) | 2008-04-23 | — | — | EP | disclosed |
| EP-1898934-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | Idenix (Cayman) Limited (KY) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007144686-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | IDENIX (CAYMAN) LIMITED (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1804811-A2 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES, PESTIVIRUSES AND HEPACIVIRUS | Idenix (Cayman) Limited (KY) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037028-A2 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES, PESTIVIRUSES AND HEPACIVIRUS | IDENIX (CAYMAN) LIMITED (KY) | 2006-04-06 | — | — | WO | disclosed |
| US-20060040944-A1 | 5-Aza-7-deazapurine derivatives for treating Flaviviridae | IDENIX PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006000922-A2 | 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING INFECTIONS WITH FLAVIVIRIDAE | IDENIX (CAYMAN) LIMITED (KY) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280850-A1 | Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus | PHOSPHO1, PNP, MTAP | ALDH1A1 2812/4885RXFP1 4614/4885KDM4E 2438/4885 |
| US-20060040944-A1 | 5-Aza-7-deazapurine derivatives for treating Flaviviridae | TPMT, NUDT15, DUSP5 | ALDH1A1 909/4885RXFP1 4733/4885KDM4E 312/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | ALDH1A1 3538/4885RXFP1 4588/4885KDM4E 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.